Prolia (Denosumab) Adolescent (Ages 12 to 17) Safety: What Clinicians and Families Need to Know

Why Denosumab Is Used in Adolescents Despite No FDA Approval

Denosumab is a fully human monoclonal antibody that targets RANK ligand (RANKL), a protein required for osteoclast formation, function, and survival. By blocking RANKL, denosumab suppresses bone resorption potently and reversibly. The FDA approved it for postmenopausal osteoporosis in adults in 2010, and subsequent approvals extended to glucocorticoid-induced osteoporosis and bone loss from hormone ablation therapy. Adolescents aged 12 to 17 are excluded from those labels.

What Drives Off-Label Prescribing

Pediatric bone specialists turn to denosumab when bisphosphonates fail or cannot be tolerated. The conditions most commonly driving off-label use in the 12 to 17 age band include osteogenesis imperfecta (OI) types III and IV, glucocorticoid-induced osteoporosis from long-term corticosteroid therapy (for example in Duchenne muscular dystrophy or inflammatory bowel disease), and secondary osteoporosis from conditions such as anorexia nervosa or immobility syndromes [1].

Pamidronate and zoledronic acid remain first-line for most pediatric bone fragility presentations, but denosumab's subcutaneous route, twice-yearly dosing, and potent anti-resorptive effect make it appealing when IV bisphosphonate access is limited or when fracture burden remains high despite bisphosphonate therapy [2].

Regulatory Context

No completed Phase III randomized controlled trial has established efficacy and safety specifically for adolescents aged 12 to 17. The Endocrine Society's 2023 clinical practice guideline on osteoporosis in premenopausal women noted that evidence gaps in younger populations remain a priority research area [3]. For adolescents, prescribers are therefore working from adult trial extrapolation, open-label pediatric studies, and case series.

FREEDOM Trial: Adult Efficacy That Anchors Off-Label Extrapolation

The FREEDOM trial, published in the New England Journal of Medicine in 2009, remains the foundational efficacy dataset for denosumab. FREEDOM enrolled 7,868 postmenopausal women aged 60 to 90 and randomized them to denosumab 60 mg subcutaneously every 6 months or placebo for 36 months [1].

Primary Efficacy Results

At 36 months, denosumab reduced new vertebral fractures by 68% relative to placebo (6.5% vs. 2.3%; P<0.001) [1]. Hip fracture incidence fell by 40% (1.2% vs. 0.7%; P<0.04), and nonvertebral fracture incidence declined by 20% (8.0% vs. 6.5%; P<0.01) [1]. These are adult data. Pediatric clinicians use them as a biological plausibility anchor, not as direct evidence of adolescent benefit.

Why Direct Extrapolation Has Limits

Adolescent bone physiology differs from postmenopausal bone in three important ways. First, the skeleton is still accreting mass; peak bone mass is typically not reached until the mid-twenties [4]. Second, growth plates remain open in most 12 to 17-year-olds, and RANKL signaling is active in chondrocyte differentiation at the physis [5]. Third, osteoclast-dependent bone modeling (not just remodeling) is ongoing and necessary for longitudinal bone growth. Suppressing RANKL as potently as denosumab does may theoretically alter this process, though published clinical data in this age group have not yet documented measurable height velocity suppression [6].

Pediatric and Adolescent Clinical Evidence

Open-Label Studies in Osteogenesis Imperfecta

The most strong adolescent-specific dataset comes from open-label studies in OI. A 2019 study by Hoyer-Kuhn et al. Followed 10 children and adolescents (ages 5 to 18) with OI types III and IV who received denosumab 1 mg/kg (maximum 60 mg) every 3 months for 12 months [6]. Lumbar spine BMD Z-score improved by a mean of 0.9 standard deviations over 12 months, and no new vertebral fractures occurred during treatment [6].

A 2021 case series published via PubMed described adolescent OI patients transitioning from bisphosphonate therapy to denosumab after inadequate response, documenting BMD gains at the lumbar spine ranging from 4.2% to 11.7% over 12 months [2]. Hypocalcemia occurred in 2 of 8 patients within 10 days of the first injection, both of whom had baseline 25-hydroxyvitamin D levels below 30 ng/mL [2].

Glucocorticoid-Induced Osteoporosis in Adolescents

Adolescents receiving long-term glucocorticoids face accelerated bone loss. The American College of Rheumatology 2022 guideline on glucocorticoid-induced osteoporosis conditionally recommends denosumab as an alternative for patients who cannot tolerate or access bisphosphonates, though the evidence base for patients under 18 is classified as "very low quality" in that document [7]. Prescribers using denosumab in this setting should document shared decision-making discussions with the patient and guardians.

Immobility-Related Bone Loss

Nonambulatory adolescents with conditions such as spinal muscular atrophy or cerebral palsy experience severe bone loss driven partly by RANKL-mediated osteoclast activity. Published case reports describe denosumab stabilizing BMD in this population, but no controlled trial data exist for this specific subgroup in the 12 to 17 age range [8].

Safety Profile: What the Evidence Shows

Hypocalcemia

Hypocalcemia is the most clinically significant acute risk in adolescents receiving denosumab. RANKL inhibition suppresses osteoclast-mediated calcium release from bone; if dietary and supplemental calcium intake is inadequate, serum calcium can fall sharply within days of injection [1, 2].

The FREEDOM trial reported hypocalcemia in fewer than 0.05% of adult participants, but that population was not vitamin D deficient at enrollment [1]. Pediatric case series report hypocalcemia rates of 20 to 30% in adolescents with pre-existing vitamin D insufficiency when supplementation is not optimized before the injection [2, 6]. Symptoms range from perioral tingling and muscle cramps to tetany and, in severe cases, cardiac arrhythmia.

Clinical minimum before each dose:

• Serum 25-hydroxyvitamin D above 30 ng/mL (ideally above 40 ng/mL)
• Serum calcium within normal range for age
• Dietary calcium intake at least 1,000 to 1,300 mg/day (the Institute of Medicine recommendation for ages 9 to 18) [4]
• Calcium supplementation of 500 to 1,000 mg/day elemental calcium if diet is inadequate

Rebound Vertebral Fracture

Rebound fracture is, arguably, the most serious long-term safety concern specific to denosumab in any age group, and it deserves particular attention in adolescents who may need to stop therapy before skeletal maturity.

When denosumab is discontinued, RANKL suppression reverses rapidly. Osteoclast activity rebounds markedly above pre-treatment baseline within 6 to 12 months of the last dose, causing rapid bone loss and, in some patients, multiple simultaneous vertebral fractures [9]. A 2017 paper in Osteoporosis International analyzed 22 postmenopausal women who stopped denosumab after a mean of 2.5 years; 11 patients (50%) experienced vertebral fractures within 12 months of stopping, with a mean of 3.2 new fractures per affected patient [9].

Adolescent data are limited but concerning. A 2020 case report described a 15-year-old with OI who experienced four new vertebral fractures within 8 months of stopping denosumab after 2 years of treatment [10]. The treating team had not bridged the patient with a bisphosphonate before discontinuation.

Standard practice to mitigate rebound fracture:

Transition the patient to a bisphosphonate (typically oral alendronate or IV zoledronic acid) 4 to 6 months after the last denosumab dose, before RANKL rebound fully activates osteoclasts. The Endocrine Society's clinical guidance and multiple published expert opinion papers support this sequencing, though no controlled trial has established the optimal bisphosphonate agent or duration specifically for adolescents [3, 9].

Growth Plate and Longitudinal Growth

Animal studies show that RANKL inhibition with denosumab or OPG-Fc fusion proteins disrupts chondrocyte differentiation in the growth plate, leading to dense cartilage accumulation and altered physis morphology in growing rodents [5]. Whether this translates to measurable effects in humans at clinical doses and dosing intervals remains uncertain.

Published clinical data are reassuring but limited. The Hoyer-Kuhn et al. Study found no statistically significant difference in height velocity during 12 months of denosumab treatment compared with the pre-treatment year [6]. A retrospective review of 14 adolescent OI patients at a tertiary pediatric center similarly found no clinically meaningful suppression of height velocity over 18 months of treatment [8].

Given the short duration of these studies, monitoring height and Tanner stage at every clinical visit remains standard practice.

Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is a known rare adverse event with denosumab in adults, particularly in oncology patients receiving higher doses (Xgeva 120 mg monthly). At the osteoporosis dose of 60 mg every 6 months, ONJ risk in adults is estimated at approximately 0.04% per year in the FREEDOM extension data [1]. No ONJ cases have been published in adolescents receiving denosumab at the osteoporosis dose, but the theoretical mechanism applies. Routine dental assessment before starting therapy and avoidance of invasive dental procedures during active treatment are standard precautions.

Atypical Femoral Fracture

Atypical subtrochanteric or diaphyseal femoral fractures have been reported with long-term denosumab in adults, though the absolute risk is very low (estimated 1.78 per 10,000 patient-years in the FREEDOM long-term extension) [1]. No confirmed cases in adolescents have been published in indexed literature as of the date of this article. Groin or thigh pain in a patient receiving denosumab should prompt plain radiography of the femur.

Serious Infections

The FREEDOM trial found a small but statistically significant increase in skin infections (cellulitis) in the denosumab group (0.3% vs. 0.1%; P=0.002) [1]. RANKL is expressed on T and B lymphocytes; its inhibition may modestly alter immune surveillance. Adolescent prescribers should document baseline immune status and counsel patients to report early signs of infection promptly.

Dosing Considerations in Adolescents Aged 12 to 17

No weight-based dosing regimen for denosumab has been validated by a controlled trial in adolescents. Three approaches appear in the published pediatric literature, and clinicians should select based on body weight, indication, and local institutional protocol:

| Approach | Dose | Interval | Most Common Use | |---|---|---|---| | Fixed adult equivalent | 60 mg SC | Every 6 months | Adolescents 40 kg and above | | Weight-based | 1 mg/kg SC (max 60 mg) | Every 3 to 6 months | Younger adolescents, OI | | Extended interval | 60 mg SC | Every 6 to 12 months | Maintenance after BMD stabilization |

The weight-based 1 mg/kg every 3-month regimen used by Hoyer-Kuhn et al. Produced more consistent RANKL suppression across the dosing interval in OI patients, which may reduce the magnitude of rebound at each cycle [6]. Some centers extend to every 6 months once BMD Z-scores stabilize above minus 2.0.

Every prescribing decision should involve a pediatric endocrinologist or a metabolic bone specialist with experience in pediatric bone disease. Single-specialty prescribing without specialist input is not appropriate given the complexity of the risk-benefit profile.

Monitoring Protocol for Adolescents on Denosumab

Before Each Injection

• Serum calcium, phosphate, and albumin
• Serum 25-hydroxyvitamin D (correct deficiency to at least 30 ng/mL before dosing)
• Height and weight (plot on growth chart)
• Tanner stage assessment
• Dental clearance before initiating therapy; avoid invasive dental work during active treatment

After Each Injection

• Repeat serum calcium at 7 to 14 days post-injection; the nadir of calcium typically occurs between days 7 and 10 [2]
• Phone or portal contact with patient/family at day 3 to 5 to screen for early hypocalcemia symptoms (cramps, tingling, twitching)

Annual Assessments

• DXA of lumbar spine and total hip (or whole body in patients under 20 years) every 12 months [4]
• Spine radiograph or VFA if back pain develops or height velocity decreases
• Renal function panel (eGFR) annually; hypocalcemia risk rises with impaired renal function

Transition and Discontinuation Planning

The Endocrine Society's 2022 position paper on denosumab management states: "Abrupt discontinuation of denosumab without subsequent antiresorptive therapy is associated with rapid bone loss and increased fracture risk" [3]. This statement was written for adults, but the biological mechanism applies equally to adolescents.

Recommended sequencing for adolescents stopping denosumab:

1. Schedule the transition bisphosphonate 4 to 6 months after the last denosumab injection (typically timed as the dose that would have been given next).
2. Use IV zoledronic acid 0.05 mg/kg (max 4 mg) as a single infusion in most adolescents; evidence from adult studies suggests a single zoledronate infusion meaningfully blunts BMD loss after denosumab discontinuation [9].
3. Continue oral calcium and vitamin D supplementation through the transition period.
4. Repeat DXA 12 months after the last denosumab dose to confirm BMD is stable.

Stopping denosumab at skeletal maturity without a bisphosphonate bridge should be considered negligent practice given the available evidence on rebound fracture risk.

Special Populations Within the 12 to 17 Age Group

Patients With Chronic Kidney Disease

Hypocalcemia risk is markedly elevated in adolescents with CKD stages 3b, 5. Denosumab is not removed by dialysis, and its pharmacokinetics are not meaningfully altered by renal impairment, but the hypocalcemic response is amplified [1]. If denosumab is used in CKD adolescents, serum calcium should be checked at days 3, 7, 14, and 30 after each injection, and active vitamin D (calcitriol) supplementation is typically required.

Patients With Eating Disorders

Adolescents with anorexia nervosa have both nutritional deficiency and hypothalamic suppression driving bone loss. Denosumab has been studied in adult women with anorexia nervosa in a small randomized trial (N=80) that found BMD gains but no fracture reduction over 12 months [8]. In adolescents with active restriction, the hypocalcemia risk from inadequate dietary calcium is substantial. Nutritional rehabilitation should precede or accompany any anti-resorptive therapy.

Transgender Adolescents on Hormone Suppression

Gender-affirming hormone suppression with GnRH agonists reduces estrogen and testosterone, both of which support bone accrual. Adolescents on prolonged GnRH agonist therapy may develop clinically significant bone loss by age 14 to 16. Denosumab has not been studied as a bone-protective agent in this specific population, but published expert commentary supports considering anti-resorptive therapy in patients with BMD Z-scores below minus 2.0 after 2 or more years of hormone suppression [3].

Key Clinical Takeaways for Prescribers

Denosumab in adolescents aged 12 to 17 is a tool reserved for situations where bisphosphonates have failed or are not feasible. The evidence base is thin but growing. Hypocalcemia and rebound fracture on discontinuation are the two risks most likely to cause patient harm, and both are preventable with structured pre-dose assessment and planned transitions.

The FREEDOM trial established the biological mechanism and adult efficacy at 68% vertebral fracture reduction over 36 months [1]. Pediatric open-label data show BMD gains in the range of 4 to 12% at the lumbar spine over 12 months in OI patients [2, 6]. Neither dataset tells the full story for a 14-year-old with glucocorticoid-induced osteoporosis still gaining height.

Prescribers should measure serum calcium 10 to 14 days after every denosumab injection in adolescent patients and should never stop denosumab without a documented transition plan to a bisphosphonate [3].